Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Revenue of Mainz Biomed B.V. (MYNZ)
Revenue in 2023 (TTM): $895.48 K
According to Mainz Biomed B.V.'s latest financial reports the company's current revenue (TTM) is $895.48 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Mainz Biomed B.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $895.48 K | $509.66 K | $-25,011,204 | $-26,295,727 | $-26,295,727 |
| 2022 | $529.88 K | $182.15 K | $-25,718,215 | $-26,387,336 | $-26,452,725 |
| 2021 | $577.35 K | $177.62 K | $-11,280,999 | $-11,695,158 | $-12,072,280 |
| 2020 | $493.57 K | $123.09 K | $-257,641 | $-586,895 | $-886,177 |
| 2019 | $281.39 K | $-61,271 | $-702,077 | $-957,055 | $-1,174,766 |